The use of pesticides such as aluminium phosphide (AlP) has increased in the recent years and improved the quantity and quality of agricultural products in a number of developing countries. The downside is that AlP causes severe chronic and acute health effects that have reached major proportions in countries such as India, Iran, Bangladesh, and Jordan. Nearly 300,000 people die due to pesticide poisoning in the world every year. Poisoning with AlP accounts for many of these deaths. Unfortunately, at the same time, there is no standard treatment for it. The aim of this article is to give a brief review of AlP poisoning and propose a treatment flowchart based on the knowledge gained so far. For this purpose we reviewed all articles on the management of AlP poisoning published from 2000 till now. Using a modified Delphi design, we have designed a handy flowchart that could be used as a guide for AlP poisoning management of patients in emergency centres.

Methanol poisoning and toxic optic neuropathy is still seen worldwide. Little attention has been paid to the persistent visual disturbances following methanol poisoning. We aimed to evaluate the outcomes of visual disturbances in methanol-poisoned patients referred to us with visual disturbances. This retrospective observational case series evaluated the outcomes of visual disturbances in patients with methanol poisoning hospitalized in Loghman Hakim and Hazrat Rasoul Akram hospitals between March 2003 and October 2009. Medical charts were evaluated for age, gender, time between consumption and hospital presentation, gastrointestinal symptoms, abnormal neurological findings at presentation and during hospital admission, arterial blood gas results, treatment modalities, history of chronic diseases, and status of vision at presentation and discharge from the hospital. The patients or their relatives were contacted 1 year after the admission date of the last patient and questioned about the status of the patients' vision at the time of hospital discharge, after discharge, and at the time of phone contacts. A total of 50 patients with methanol poisoning and visual disturbances at presentation survived. Thirty-seven cases were followed; 16 showed visual disturbance improvement before hospital discharge, and 21 had visual disturbance after discharge. Visual disturbances were classified into two groups: severe to total blindness and blurred/snowfield vision. Patients were also grouped into one of four categories: group I: patients whose blurred or snowfield vision completely recovered within up to a maximum of 2 weeks after discharge (n=7); group II, the patients who were blind at the time of discharge (n=5) and partially recovered within a maximum of 3-4 weeks; group III, the patients who were blind at the time of discharge and gained no improvement in their vision (n=5); group IV, who were blind at the time of discharge, partially recovered within few days to approximately 1 month and experienced reduced vision and blindness after about a maximum of 9 months (n=4). Patients whose visual disturbances improved with treatment and the patients in group I were considered as transient (n=23) and groups II, III, and IV as permanent visual disturbance cases (n=14). Significant difference was not seen in age, sex, elapsed time to presentation, gastrointestinal symptoms, abnormal neurological and CT findings, and arterial blood gas results at presentation between the transient and permanent visual disturbance groups. No association existed between the visual disturbance and abnormal neurological and CT findings. Blurred or snowfield vision in methanol poisoning resolved. However, outcomes of the blindness cannot be predicted. Insome patients, blindness improves but these patients eventually experience reduced vision afterwards.

Methadone is one of the most popular synthetic opioids in the world with some favorable properties making it useful both in the treatment of moderate to severe pain and for opioid addiction. Increased use of methadone has resulted in an increased prevalence of its toxicity, one aspect of which is cardiotoxicity. In this paper, we review the effects of methadone on the heart as well as cardiac concerns in some special situations such as pregnancy and childhood. Methods: We searched for the terms methadone, toxicity, poisoning, cardiotoxicity, heart, dysrhythmia, arrhythmia, QT interval prolongation, torsade de pointes, and Electrocardiogram (ECG) in bibliographical databases including TUMS digital library, PubMed, Scopus, and Google Scholar. This review includes relevant articles published between 2000 and 2013. The main cardiac effects of methadone include prolongation of QT interval and torsade de pointes. Other effects include changes in QT dispersion, pathological U waves, Taku-Tsubo syndrome (stress cardiomyopathy), Brugada-like syndrome, and coronary artery diseases. The aim of this paper is to inform physicians and health care staff about these adverse effects. Effectiveness of methadone in the treatment of pain and addiction should be weighed against these adverse effects and physicians should consider the ways to lessen such undesirable effects. This article presents some recommendations to prevent heart toxicity in methadone users.

To describe an outbreak of lead poisoning among opium users in the Islamic Republic of Iran and estimate the number of affected people in the country. We used data from the country's largest poison treatment centre to illustrate the epidemiology of an outbreak of lead poisoning in oral opium users. We describe the government's referral and treatment guidelines in response to the outbreak. Based on the number of individuals treated and previous studies on the prevalence of oral opium use we estimated the total number of people at risk of lead-contaminated opium nationwide. In February 2016, we noticed a steep increase in the numbers of oral opium users referred to our poison treatment centre with abdominal pain, anaemia and constipation. Numbers peaked in June 2016 but the outbreak was ongoing in August 2017. The mean blood lead level in a sample of 80 patients was 140.3 µg/dL (standard deviation: 122.6). Analysis of an illegal opium sample showed 3.55 mg lead in 1 g opium. Treatment was exposure reduction with opioid substitutes and laxatives, or chelation therapy if indicated. Over 7 months, 4294 poison cases were seen at main referral hospitals in Tehran out of an estimated 31 914 oral opium users in the city. We estimate more than 260 000 out of 773 800 users nationwide remain untreated and at risk of poisoning. Lead-contaminated opium and heroin that has transited through the Iranian markets is a global risk and highlights a need for better monitoring of illegal drug supplies.